Pembrolizumab: living up to expectations

Blocking programmed death 1 (PD-1) signaling in relapsed Hodgkin lymphoma results in high response rates,(1-3) and Chen et al, in this issue of Blood, report the outcome of patients treated with pembrolizumab with 2 years of follow-up.(4) They confirm that responses in patients treated with this PD-1-blocking antibody are durable and find that patients continue to tolerate PD-1 blockade well with extended treatment.